These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9930564)

  • 1. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Lewis BE; Bick RL; Walenga JM
    Semin Hematol; 1999 Jan; 36(1 Suppl 1):42-56. PubMed ID: 9930564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of direct thrombin inhibitors in comparison with glycosaminoglycans.
    Markwardt F
    Semin Thromb Hemost; 2001 Oct; 27(5):523-30. PubMed ID: 11668423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulant agents: direct thrombin inhibitors.
    Nutescu EA; Shapiro NL; Chevalier A
    Clin Geriatr Med; 2006 Feb; 22(1):33-56, viii. PubMed ID: 16377466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Walenga JM; Bick RL
    Med Clin North Am; 1998 May; 82(3):569-86. PubMed ID: 9646780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
    Callas D; Fareed J
    Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin agents: the new class of anticoagulant and antithrombotic drugs.
    Fareed J; Lewis BE; Callas DD; Hoppensteadt DA; Walenga JM; Bick RL
    Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S45-55. PubMed ID: 10726036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From natural to synthetic multisite thrombin inhibitors.
    Lombardi A; De Simone G; Galdiero S; Staiano N; Nastri F; Pavone V
    Biopolymers; 1999; 51(1):19-39. PubMed ID: 10380350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirudin as alternative anticoagulant--a historical review.
    Markwardt F
    Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of coagulation factors: advances in antithrombotic therapy.
    Bauer KA
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():15-24. PubMed ID: 12073176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the design of low molecular weight thrombin inhibitors.
    Srivastava S; Goswami LN; Dikshit DK
    Med Res Rev; 2005 Jan; 25(1):66-92. PubMed ID: 15389730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
    Brill-Edwards P; Van Ryn-McKenna J; Cai L; Ofosu FA; Buchanan MR
    Thromb Haemost; 1992 Oct; 68(4):424-7. PubMed ID: 1448774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.